Drug
E-3810 clinical trials
Also written Lucitanib, AL3810 and E-3810.
- studies test it
- 14
- open now
- 0
- in phase 3
- 4
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 3
Haihe Biopharma Co., Ltd. (4) · Eisai Co., Ltd. (3) · Clovis Oncology, Inc. (3) · Institut de Recherches Internationales Servier (2) · Eisai Inc. (1) · Teresa Helsten, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses E-3810 is read from its arms, and is right about nine times in ten.
Testing it · 14
- Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After ChemotherapyCompletedPhase 2Haihe Biopharma Co., Ltd.NCT07824505Written as lucitanib 15 mg QD
- A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast CancerCompletedPhase 2Institut de Recherches Internationales ServierNCT02053636Written as lucitanib
- Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid TumorsCompletedPhase 1/2Institut de Recherches Internationales ServierNCT01283945Written as Lucitanib
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorSuspendedPhase 1/2Clovis Oncology, Inc.NCT04042116Written as Lucitanib
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerTerminatedPhase 2Clovis Oncology, Inc.NCT02202746Written as Lucitanib
- This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in PatientsStatus unknownPhase 2/3Haihe Biopharma Co., Ltd.NCT04254471Written as AL3810
- A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsTerminatedPhase 2Clovis Oncology, Inc.NCT02109016Written as Lucitanib
- Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway AberrationsWithdrawnPhase 2Teresa Helsten, MDNCT02747797Written as Lucitanib
- Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownPhase 1Haihe Biopharma Co., Ltd.NCT03260179Written as AL3810
- Study of the AL3810 in the Treatment of Advanced Solid TumorCompletedPhase 1Haihe Biopharma Co., Ltd.NCT03117101Written as Lucitanib
- Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)CompletedPhase 2/3Eisai Co., Ltd.NCT01397448Written as E3810
- A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg TabletsCompletedPhase 1Eisai Inc.NCT01153659Written as E3810
- Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux EsophagitisCompletedPhase 2/3Eisai Co., Ltd.NCT00770913Written as E3810
- A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux DiseaseCompletedPhase 3Eisai Co., Ltd.NCT00165646Written as E3810
Given in every arm · 2 — E-3810 is usual care beside what is tested
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedPhase 1/2pharmaand GmbHNCT03992131Written as Lucitanib
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnPhase 1/2Bristol-Myers SquibbNCT04151563Written as lucitanib